Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
NW Andersson, H Svanström, M Lund… - International journal of …, 2018 - Elsevier
Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
NW Andersson, H Svanström… - International …, 2018 - internationaljournalofcardiology.com
Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
NW Andersson, H Svanström, M Lund… - … Journal of Cardiology, 2018 - europepmc.org
Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
NW Andersson, H Svanström… - International …, 2018 - pubmed.ncbi.nlm.nih.gov
Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …